Adarza Biosystems Inc.’s Ziva platform can simultaneously detect hundreds of proteins, antibodies, or substrates from a single drop of blood, plasma or serum, providing insight into an individual’s immune response. That could be critical for both surveillance and diagnostic purposes as the nation prepares for a likely second wave of the novel coronavirus in the fall when multiple respiratory pathogens will be circulating.
Ziva uses arrayed imaging reflectometry (AIR), a technology co-developed by Ben Miller, a founder of St. Louis-based Adaraza and professor of dermatology, biochemistry and biophysics as well as biomedical engineering at the University of Rochester in New York.
READ THE FULL ARTICLE